Ilse Van Hove
Overview
Explore the profile of Ilse Van Hove including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lindenmayer J, Khan A, Eerdekens M, Van Hove I, Kushner S
Eur Neuropsychopharmacol
. 2006 Oct;
17(2):138-44.
PMID: 17049818
Subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (Study A and Study B) after participating in 12-week studies of long-acting injectable risperidone [Kane, J.M., Eerdekens, M.,...
12.
Mintzer J, Greenspan A, Caers I, Van Hove I, Kushner S, Weiner M, et al.
Am J Geriatr Psychiatry
. 2006 Mar;
14(3):280-91.
PMID: 16505133
Objective: The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD). Method: The authors conducted a randomized, eight-week, double-blind,...
13.
Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey P, Kopala L, et al.
Am J Psychiatry
. 2005 May;
162(5):947-53.
PMID: 15863797
Objective: The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment cornerstone...
14.
Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders
Gagiano C, Read S, Thorpe L, Eerdekens M, Van Hove I
Psychopharmacology (Berl)
. 2005 Jan;
179(3):629-36.
PMID: 15668818
Rationale: Function in society can be severely affected by disruptive behaviors in adults. Objectives: To examine the efficacy and safety of risperidone in the treatment of disruptive behavior disorders in...
15.
Eerdekens M, Van Hove I, Remmerie B, Mannaert E
Schizophr Res
. 2004 Jul;
70(1):91-100.
PMID: 15246468
The pharmacokinetics and tolerability of long-acting risperidone (Risperdal Consta) were evaluated in a multicenter, prospective, open-label, 15-week study of 86 patients with schizophrenia. Subjects stabilized on 2, 4 or 6...